Table 3 Efficacy and modalities of treatment at baseline and 9 months
Hizentra N = 117 | |
|---|---|
Dose at baseline (g/kg/injection), N | 113 |
Mean ± SD | 0.2 ± 0.9 |
Median [range] | 0.1 [0.0;7.0] |
Dose at follow-up (g/kg/injection), N | 113 |
Mean ± SD | 0.3 ± 1.0 |
Median [range] | 0.1 [0.0;7.0] |
Schedule of injections at baseline, N | 115 |
≤ 7 days, n (%) | 111 (96.5 %) |
> 7 days, n (%) | 4 (3.5 %) |
Schedule of injections at follow-up, N | 116 |
≤ 7 days, n (%) | 107 (92.2 %) |
> 7 days, n (%) | 9 (7.8 %) |
Trough IgG titer at baseline (g/L), N | 106 |
Mean ± SD | 9.0 ± 6.6 |
Median [range] | 7.7 [0.1;49.5] |
Trough IgG titers (g/L) at follow-up, N | 95 |
Mean ± SD | 9.0 ± 3.3 |
Median [range] | 8.3 [3.4;24.0] |
Number of infections at follow-up, N | 99 |
Mean ± SD | 1.0 ± 1.6 |
Median [range] | 0.0 [0.0;8.0] |
Yearly rate of infection, mean ± SD | 1.2 ± 1.9 |
Worsening of immunodeficiency at follow-up, N | 98 |
Yes, n (%) | 1 (5.3 %) |